Research in the Department of Periodontology focuses on immunological and genetic aspects of the pathogenesis of periodontal diseases, chemotherapeutic prevention, and the treatment of periodontal diseases, the biology of bone and cartilage growth and differentiation.
The effects of sex hormones, vitamin D and various growth factors on cartilage cell growth and differentiation
The use of sustained release delivery systems in the treatment of periodontal disease and other disease-related problems have also been examined
Studies on the differences in monocyte function in different forms of periodontal diseases as well as genetic linkage studies on families with suspected genetically inherited forms of periodontal diseases
Our department has a long history and tradition of research. Our major emphasis and strengths have been directed to the basic sciences.
The biology of bone and cartilage has provided a major line of research. This has included studies on structural aspects, biochemistry and the control of bone and cartilage growth and development; the effect of various biomaterials on bone, in particular those used in implant dentistry; and aspects of the immune system and its influence on the development of the periodontal diseases. In particular, the influence of bacterial endotoxins on the secretion of inflammatory mediators from monocytes and macrophages have been studied as well as the mechanisms involved in this process.
The variation in these secretory phenomena in patients with different types of periodontal diseases also continues to be of interest.
Studies have also been carried out in the field of lone substitutes for grafting as well as studies on the effects of the surface characteristics of implant materials on the cellular response to them.
On a clinical level, the department has been very active in developing a new biodegradable, sustained release delivery device for the targeted release of drugs in the subgingival area. A product that delivers chlorhexidine has recently been approved by the Israel Ministry of Health and has been released for clinical use under prescription.
This development, which has great therapeutic and commercial potential, is the result of a relationship between the Hebrew University-Hadassah Dental and Medical Faculties and Israeli Industry. The patent for the targeted delivery system was acquired from the Hebrew University and Hadassah by Israel's largest chemical conglomerate, who set up a subsidiary, called Perio Products, to develop and manufacture sustained release delivery systems.
The close cooperation that developed between the academic and industrial partners has led to the successful production of the Perio Chip for use in the treatment of periodontal diseases and the development of numerous other products and ideas that are based on sustained and targeted release technology. Perio Products was recently acquired by Dexcel Pharma Technologies Ltd./A Dexxon Company.